Page last updated: 2024-11-12
f-amidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
F-amidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11589584 |
| CHEMBL ID | 1962723 |
| CHEMBL ID | 1910973 |
| CHEBI ID | 188065 |
| SCHEMBL ID | 1979695 |
| MeSH ID | M0496777 |
Synonyms (12)
| Synonym |
|---|
| CHEBI:188065 |
| n-[(2s)-1-amino-5-[(1-amino-2-luoroethylidene)amino]-1-oxopentan-2-yl]benzamide |
| f-amidine |
| CHEMBL1962723 , |
| CHEMBL1910973 , |
| bdbm50355658 |
| SCHEMBL1979695 |
| 877617-45-3 |
| n-[(2s)-1-amino-5-[(1-amino-2-fluoroethylidene)amino]-1-oxopentan-2-yl]benzamide |
| (s,z)-n-(1-amino-5-((1-amino-2-fluoroethylidene)amino)-1-oxopentan-2-yl)benzamide |
| bdbm50581391 |
| AKOS040745786 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Since D-amino amino acids often possess enhanced in cellulo stability, and perhaps unique selectivities, we synthesized a series of D-amino acid analogs of our pan-PAD inhibitor Cl-amidine, hypothesizing that this change would provide inhibitors with enhanced pharmacokinetic properties." | ( D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. Anguish, L; Bicker, KL; Cameron, MD; Chumanevich, AA; Chumanevich, AP; Coonrod, SA; Cui, X; Hofseth, LJ; Subramanian, V; Thompson, PR; Witalison, E; Zhang, X, 2012) | 0.38 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The bioavailability of this compound suggests that F-amidine will be a powerful chemical probe of PAD4 function that can be used to dissect the roles of this enzyme in both rheumatoid arthritis and transcriptional control." | ( A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. Knuckley, B; Lee, YH; Luo, Y; Stallcup, MR; Thompson, PR, 2006) | 0.58 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| N-acylglycine | An N-acyl-amino acid in which amino acid specified is glycine. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (4)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 (µMol) | 110.8000 | 0.0000 | 1.0680 | 10.0000 | AID1813072; AID1813073 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | IC50 (µMol) | 110.8000 | 0.0000 | 1.1040 | 10.0000 | AID1813072; AID1813073 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | IC50 (µMol) | 110.8000 | 0.0000 | 1.4651 | 10.0000 | AID1813072; AID1813073 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | IC50 (µMol) | 110.8000 | 0.0000 | 1.1463 | 10.0000 | AID1813072; AID1813073 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (30)
Molecular Functions (15)
Ceullar Components (19)
Bioassays (15)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1364667 | Ratio of Kinact to Ki for recombinant His6-tagged PAD3 (unknown origin) preincubated for 10 mins followed by BAA substrate addition measured after 15 mins by COLDER assay | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Development of a Selective Inhibitor of Protein Arginine Deiminase 2. |
| AID712879 | Ratio of Kinact to Ki for PAD1 | 2012 | ACS medicinal chemistry letters, Oct-26, Volume: 3, Issue:12 | D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. |
| AID1196525 | Inhibition of PAD4 (unknown origin) using N-alpha-benzoyl-L-arginine ethyl ester as substrate assessed as citrulline production after 15 mins by COLDER assay | 2015 | Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3 | Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors. |
| AID712874 | Selectivity ratio of Kinact to Ki for PAD1 to Kinact to Ki for PAD4 | 2012 | ACS medicinal chemistry letters, Oct-26, Volume: 3, Issue:12 | D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. |
| AID1364666 | Ratio of Kinact to Ki for recombinant human PAD2 expressed in Escherichia coli BL21(DE3)pLysS cells preincubated for 10 mins followed by BAEE substrate addition measured after 15 mins by COLDER assay | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Development of a Selective Inhibitor of Protein Arginine Deiminase 2. |
| AID712877 | Selectivity ratio of Kinact to Ki for PAD1 to Kinact to Ki for PAD2 | 2012 | ACS medicinal chemistry letters, Oct-26, Volume: 3, Issue:12 | D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. |
| AID1196527 | Ratio of Kinact to Ki for PAD2 (unknown origin) using N-alpha-benzoyl-L-arginine ethyl ester as substrate assessed as citrulline production after 15 mins by COLDER assay | 2015 | Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3 | Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors. |
| AID1364668 | Ratio of Kinact to Ki for recombinant full length N-terminal GST-tagged human PAD4 expressed in Escherichia coli Rosetta cells preincubated for 10 mins followed by BAEE substrate addition measured after 15 mins by COLDER assay | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Development of a Selective Inhibitor of Protein Arginine Deiminase 2. |
| AID712876 | Ratio of Kinact to Ki for PAD4 | 2012 | ACS medicinal chemistry letters, Oct-26, Volume: 3, Issue:12 | D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. |
| AID712878 | Ratio of Kinact to Ki for PAD3 | 2012 | ACS medicinal chemistry letters, Oct-26, Volume: 3, Issue:12 | D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. |
| AID1813073 | Inhibition of PDE4 (unknown origin) in absence of calcium by colorimetric assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Peptidylarginine deiminases 4 as a promising target in drug discovery. |
| AID712875 | Selectivity ratio of Kinact to Ki for PAD1 to Kinact to Ki for PAD3 | 2012 | ACS medicinal chemistry letters, Oct-26, Volume: 3, Issue:12 | D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. |
| AID1364665 | Ratio of Kinact to Ki for recombinant His6-tagged PAD1 (unknown origin) preincubated for 10 mins followed by BAEE substrate addition measured after 15 mins by COLDER assay | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Development of a Selective Inhibitor of Protein Arginine Deiminase 2. |
| AID1813072 | Inhibition of PDE4 (unknown origin) in presence of calcium by colorimetric assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Peptidylarginine deiminases 4 as a promising target in drug discovery. |
| AID712880 | Ratio of Kinact to Ki for PAD2 | 2012 | ACS medicinal chemistry letters, Oct-26, Volume: 3, Issue:12 | D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.68
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.68) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||